Clinical Trials Tracker
Active and completed Phase 1–3 trials for research peptides. All NCT numbers link to ClinicalTrials.gov for live data. Last updated: October 2026.
Semaglutide — Obesity
Effect of Semaglutide on Body Weight in Subjects with Obesity (STEP 1)
Landmark trial demonstrating 14.9% mean weight reduction with 2.4 mg weekly semaglutide vs 2.4% placebo over 68 weeks.
Semaglutide — Cardiovascular Disease, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT)
20% reduction in major adverse cardiovascular events (MACE) in adults with CVD and obesity but without diabetes.
Tirzepatide — Obesity
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Established a 20.9% mean weight loss benchmark at 15 mg weekly, exceeding all prior approved pharmacotherapy.
Tirzepatide — Obesity (Weight Maintenance)
Tirzepatide for Weight Management After Initial Weight Loss (SURMOUNT-3)
Assessed tirzepatide for maintenance of weight loss following lifestyle intervention, showing continued benefit.
Retatrutide — Obesity
Retatrutide (LY3437943) Phase 2 Obesity Study
Phase 2 showing up to 24.2% body weight reduction at 48 weeks with 12 mg dose — approaching bariatric surgery outcomes.
Retatrutide — Obesity
Retatrutide Phase 3 — TRIUMPH-1
Phase 3 confirmatory trial evaluating 12 mg retatrutide weekly for obesity treatment. Primary endpoint: ≥5% weight reduction vs placebo.
TB-500 (Thymosin Beta-4) — Cardiac Remodelling
Thymosin Beta-4 for Prevention of Pressure Overload Induced Cardiac Remodelling
Phase 2 assessment of Thymosin Beta-4 for cardiac protection, building on preclinical data showing angiogenesis and stem cell recruitment.
PT-141 (Bremelanotide) — Hypoactive Sexual Desire Disorder
Bremelanotide (PT-141) for Hypoactive Sexual Desire Disorder in Women
Phase 3 RECONNECT trial leading to FDA approval of Vyleesi (bremelanotide) in 2019 for premenopausal women with HSDD.
Ipamorelin — Postoperative Ileus
Ipamorelin for Treatment of Postoperative Ileus
Phase 2 clinical trial evaluating ipamorelin's prokinetic effects for accelerating gut motility recovery following abdominal surgery.
Tesamorelin — HIV-Associated Lipodystrophy
Tesamorelin for Reduction of Excess Abdominal Fat in HIV-Infected Patients
Phase 3 confirming tesamorelin's efficacy for visceral fat reduction in HIV patients, supporting its FDA approval as Egrifta for HIV-associated lipodystrophy.
Thymosin Alpha-1 — COVID-19 (Severe)
Thymosin Alpha-1 for Treatment of Severe COVID-19
Phase 2 trial assessing Thymosin Alpha-1's immune-modulating effects in severe COVID-19, following evidence of its immunostimulatory properties in earlier infectious disease research.
BPC-157 — Inflammatory Bowel Disease
BPC-157 Oral Formulation — Phase 1/2 (PL-10 Programme)
Phase 1/2 evaluation of BPC-157 oral capsule (PL-10) for IBD, translating extensive preclinical data into a first-in-class human GI healing trial.
GHK-Cu — Chronic Wounds
GHK-Cu in Chronic Wound Management — Phase 2
Investigator-initiated trials evaluating topical and injectable GHK-Cu formulations for chronic wound healing in diabetic foot ulcers and surgical site management.
CJC-1295 + Ipamorelin — Adult Growth Hormone Deficiency
CJC-1295 / Ipamorelin Combination for Adult GH Deficiency
Phase 2 investigator-initiated studies assessing the CJC-1295/Ipamorelin combination for restoring physiological GH pulsatility in adults with GH deficiency.
Epithalon — Immunosenescence / Age-Related Decline
Epithalon (Epitalon) for Age-Related Immune Decline — Phase 2
Ongoing Phase 2 studies extending Khavinson's longitudinal work on Epithalon's immune-restoring and longevity-associated effects in elderly patient cohorts.